Nom du produit:2,5-difluoro-4-(trifluoromethyl)benzaldehyde

IUPAC Name:2,5-difluoro-4-(trifluoromethyl)benzaldehyde

CAS:134099-33-5
Formule moléculaire:C8H3F5O
Pureté:95%+
Numéro de catalogue:CM458962
Poids moléculaire:210.1

Unité d'emballage Stock disponible Prix($) Quantité
CM458962-250mg 3-4 Weeks ʼnĽŢ
CM458962-500mg 4-5 Weeks ȎǤNJ
CM458962-1g 4-5 Weeks ŢǤǤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:134099-33-5
Formule moléculaire:C8H3F5O
Point de fusion:-
Code SMILES:FC1=CC(C=O)=C(F)C=C1C(F)(F)F
Densité:
Numéro de catalogue:CM458962
Poids moléculaire:210.1
Point d'ébullition:
N° Mdl:MFCD28714769
Stockage:

Column Infos

Nelutroctiv
The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility”. Heart failure (HF) is a lifelong clinical syndrome and remains a major societal concern. Cardiac myosin activators constitute a new class of inotropes and are found to be a viable therapeutic approach for increasing myocardial contractility.
CK-136 is a small molecule cardiac troponin activator that is discovered under a previous joint research program between Cytokinetics and Amgen. It acts on the sarcomere and is designed to improve myocardial contractility by sensitizing cardiac troponin to calcium, increasing actin-myosin cross bridge formation during each cardiac cycle. CK-136 is developed as a potential treatment for heart failure (HF) with reduced ejection fraction (HFrEF) and other types of heart failure, and currently under phase 1 clinical investigation.

Related Products